FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023952988> ?p ?o ?g. }

• W2023952988 endingPage "1939" @default.
• W2023952988 startingPage "1931" @default.
• W2023952988 abstract "Background The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials comparing the effectiveness of one targeted agent against another have been reported. We did a randomised phase 3 study comparing axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor (VEGF) receptors, with sorafenib, an approved VEGF receptor inhibitor, as second-line therapy in patients with metastatic renal cell cancer. Methods We included patients coming from 175 sites (hospitals and outpatient clinics) in 22 countries aged 18 years or older with confirmed renal clear-cell carcinoma who progressed despite first-line therapy containing sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. Patients were stratified according to Eastern Cooperative Oncology Group performance status and type of previous treatment and then randomly assigned (1:1) to either axitinib (5 mg twice daily) or sorafenib (400 mg twice daily). Axitinib dose increases to 7 mg and then to 10 mg, twice daily, were allowed for those patients without hypertension or adverse reactions above grade 2. Participants were not masked to study treatment. The primary endpoint was progression-free survival (PFS) and was assessed by a masked, independent radiology review and analysed by intention to treat. This trial was registered on ClinicalTrials.gov, number NCT00678392. Findings A total of 723 patients were enrolled and randomly assigned to receive axitinib (n=361) or sorafenib (n=362). The median PFS was 6·7 months with axitinib compared to 4·7 months with sorafenib (hazard ratio 0·665; 95% CI 0·544–0·812; one-sided p<0·0001). Treatment was discontinued because of toxic effects in 14 (4%) of 359 patients treated with axitinib and 29 (8%) of 355 patients treated with sorafenib. The most common adverse events were diarrhoea, hypertension, and fatigue in the axitinib arm, and diarrhoea, palmar-plantar erythrodysaesthesia, and alopecia in the sorafenib arm. Interpretation Axitinib resulted in significantly longer PFS compared with sorafenib. Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma. Funding Pfizer Inc." @default.
• W2023952988 created "2016-06-24" @default.
• W2023952988 creator A5006742120 @default.
• W2023952988 creator A5015598872 @default.
• W2023952988 creator A5020353650 @default.
• W2023952988 creator A5024147987 @default.
• W2023952988 creator A5025529463 @default.
• W2023952988 creator A5028789952 @default.
• W2023952988 creator A5031580649 @default.
• W2023952988 creator A5032105752 @default.
• W2023952988 creator A5039180386 @default.
• W2023952988 creator A5047852139 @default.
• W2023952988 creator A5049048398 @default.
• W2023952988 creator A5049672639 @default.
• W2023952988 creator A5052978985 @default.
• W2023952988 creator A5058934672 @default.
• W2023952988 creator A5059063118 @default.
• W2023952988 creator A5063293745 @default.
• W2023952988 creator A5072800302 @default.
• W2023952988 creator A5073727558 @default.
• W2023952988 creator A5076633444 @default.
• W2023952988 creator A5082009347 @default.
• W2023952988 creator A5084565053 @default.
• W2023952988 date "2011-12-01" @default.
• W2023952988 modified "2023-10-17" @default.
• W2023952988 title "Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial" @default.
• W2023952988 cites W1914288745 @default.
• W2023952988 cites W1965664963 @default.
• W2023952988 cites W1965874702 @default.
• W2023952988 cites W1999966467 @default.
• W2023952988 cites W2033240546 @default.
• W2023952988 cites W2034680734 @default.
• W2023952988 cites W2097415899 @default.
• W2023952988 cites W2099752220 @default.
• W2023952988 cites W2100669312 @default.
• W2023952988 cites W2103506609 @default.
• W2023952988 cites W2106453307 @default.
• W2023952988 cites W2108036229 @default.
• W2023952988 cites W2118677643 @default.
• W2023952988 cites W2123769946 @default.
• W2023952988 cites W2139248078 @default.
• W2023952988 cites W2142297664 @default.
• W2023952988 cites W2146950212 @default.
• W2023952988 cites W2149032069 @default.
• W2023952988 cites W2149456801 @default.
• W2023952988 cites W2152190103 @default.
• W2023952988 cites W2156408558 @default.
• W2023952988 cites W2157262448 @default.
• W2023952988 cites W2162424705 @default.
• W2023952988 cites W2206164324 @default.
• W2023952988 cites W2590252682 @default.
• W2023952988 cites W2591251674 @default.
• W2023952988 cites W2768600953 @default.
• W2023952988 doi "https://doi.org/10.1016/s0140-6736(11)61613-9" @default.
• W2023952988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22056247" @default.
• W2023952988 hasPublicationYear "2011" @default.
• W2023952988 type Work @default.
• W2023952988 sameAs 2023952988 @default.
• W2023952988 citedByCount "1589" @default.
• W2023952988 countsByYear W20239529882012 @default.
• W2023952988 countsByYear W20239529882013 @default.
• W2023952988 countsByYear W20239529882014 @default.
• W2023952988 countsByYear W20239529882015 @default.
• W2023952988 countsByYear W20239529882016 @default.
• W2023952988 countsByYear W20239529882017 @default.
• W2023952988 countsByYear W20239529882018 @default.
• W2023952988 countsByYear W20239529882019 @default.
• W2023952988 countsByYear W20239529882020 @default.
• W2023952988 countsByYear W20239529882021 @default.
• W2023952988 countsByYear W20239529882022 @default.
• W2023952988 countsByYear W20239529882023 @default.
• W2023952988 crossrefType "journal-article" @default.
• W2023952988 hasAuthorship W2023952988A5006742120 @default.
• W2023952988 hasAuthorship W2023952988A5015598872 @default.
• W2023952988 hasAuthorship W2023952988A5020353650 @default.
• W2023952988 hasAuthorship W2023952988A5024147987 @default.
• W2023952988 hasAuthorship W2023952988A5025529463 @default.
• W2023952988 hasAuthorship W2023952988A5028789952 @default.
• W2023952988 hasAuthorship W2023952988A5031580649 @default.
• W2023952988 hasAuthorship W2023952988A5032105752 @default.
• W2023952988 hasAuthorship W2023952988A5039180386 @default.
• W2023952988 hasAuthorship W2023952988A5047852139 @default.
• W2023952988 hasAuthorship W2023952988A5049048398 @default.
• W2023952988 hasAuthorship W2023952988A5049672639 @default.
• W2023952988 hasAuthorship W2023952988A5052978985 @default.
• W2023952988 hasAuthorship W2023952988A5058934672 @default.
• W2023952988 hasAuthorship W2023952988A5059063118 @default.
• W2023952988 hasAuthorship W2023952988A5063293745 @default.
• W2023952988 hasAuthorship W2023952988A5072800302 @default.
• W2023952988 hasAuthorship W2023952988A5073727558 @default.
• W2023952988 hasAuthorship W2023952988A5076633444 @default.
• W2023952988 hasAuthorship W2023952988A5082009347 @default.
• W2023952988 hasAuthorship W2023952988A5084565053 @default.
• W2023952988 hasConcept C126322002 @default.
• W2023952988 hasConcept C143998085 @default.
• W2023952988 hasConcept C183713625 @default.
• W2023952988 hasConcept C185592680 @default.
• W2023952988 hasConcept C190283241 @default.

• next